Inside Pfizer’s $100 billion blockbuster offer for AstraZeneca. Is a more favorable tax rate in Britain the real reason behind the deal?
For this story and more tune in tonight.
Inside Pfizer’s $100 billion blockbuster offer for AstraZeneca. Is a more favorable tax rate in Britain the real reason behind the deal?
For this story and more tune in tonight.